SEP 30, 2015 7:30 AM PDT

Humanized NSGTM Mice for Evaluation of Immuno-Oncology Therapeutics

Speaker

Abstract

Using the NSGTM mouse (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ), JAX In Vivo Pharmacology Services has combined the human CD34+ hematopoietic stem cell engrafted NSGTM (hu-CD34 NSGTM) with human patient derived xenograft (PDX) to create a platform for humanized preclinical studies in immuno-oncology. Non-HLA matched PDX tumors grow well in hu-CD34 NSGTM, despite concerns over transplant rejection. When unmatched human PDX was engrafted in NSGTM or hu-CD34 NSGTM tumor growth rate was similar, indicating the human immune cells did not influence tumor growth. Next, hu-CD34 NSGTM mice were transplanted with a PDX breast or lung tumor in which 56.9% and 89.1% of the cells in the tumor expressed PD-L1, respectively. When PD-L1 is bound to PD1 on T cells, the T cells are rendered anergic. When treated with Keytruda, an antibody that blocks PD1/PD-L1 binding, tumor growth was significantly diminished. This showed human T cells could be induced to respond to PDX following treatment with a check-point inhibitor. Recognizing that CTL’s are not the only cell population important in immuno-oncology, we are now evaluating NSGTM-SGM3 mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ) for humanization and co-engraftment of PDX. These mice express human IL-3, GM-CSF, and KIT ligand that allow improved development of regulatory T cells (Treg) and myeloid cells. Within the tumor, Treg are implicated in suppression of T effector function. Myeloid derived suppressor cells (MDSC) and tumor associated macrophages (TAM) also diminish immune responses. Engraftment kinetics comparing hu-CD34 NSGTM to hu-CD34 NSGTM-SGM3 hosts show more rapid expansion of CD3+ T cells, Treg, and CD33+ myeloid cells in the NSGTM-SGM3 hosts. Several PDX tumors have successfully engrafted in the hu-CD34 NSGTM-SGM3 hosts, enabling further research into both the basic biology and development of therapeutics in human immuno-oncology.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
SEP 09, 2021 8:00 AM PDT
C.E. CREDITS
SEP 09, 2021 8:00 AM PDT
Date: September 09, 2021 Time: 8:00am (PDT), 11:00am (EDT) Human pluripotent stem cells (PSCs) hold great potentials in regenerative therapies. In this webinar, Chao will first present the c...
SEP 08, 2021 9:00 AM PDT
SEP 08, 2021 9:00 AM PDT
Date: September 8, 2021 Time: 9:00am (PDT), 12:00pm (EDT) Implanted biomedical devices comprise a major component of modern medicine and are essential for many clinical applications ranging...
SEP 30, 2015 7:30 AM PDT

Humanized NSGTM Mice for Evaluation of Immuno-Oncology Therapeutics



Show Resources
Loading Comments...
Show Resources